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Abstract 
Background; Exercise options for those with moderate to high levels of disability are 
limited.  The aim of the study was to evaluate the feasibility of a progressive, four 
week lower limb cycling programme using active-passive trainers (APT’s) on 
spasticity, cardiovascular fitness, function and quality of life in people with moderate 
to severe MS. 
Methods; Participants were in-patients in the Physical Disability Rehabilitation Unit, 
Queen Elizabeth University Hospital, Glasgow, UK and randomised to APT + usual 
care or usual care only.  The APT group received 30 minutes of APT (2 minutes 
passive warm up, 26 minutes active cycling, 2 minutes passive cool down), five days 
per week for 4 weeks.  Outcome measures; Oxygen Uptake Efficiency Slope, 
Modified Ashworth Scale, Multiple Sclerosis Spasticity Scale, Functional 
Independence Measure, Timed 25 foot walk test and the MSQOL-54, were taken 
before and after the intervention period.  Symmetry, distance cycled and active 
participation were also recorded for each cycling session.   
Results; 24 participants were recruited, 15 to the intervention and 9 to the control 
group.  There was a 100% adherence to the intervention and a significant increase in 
average speed, power output and distance cycled (p< 0.001 for each) over the four 
weeks.  There were no adverse events and both groups improved in average scores 
for all outcome measures.   
Conclusions; APT cycling was well tolerated, while the cycling parameters 
improved it was difficult to separate the effects of the therapy programme and APT 
cycling. A longer duration, fully powered trial in a community setting is merited. 
Introduction  
Multiple sclerosis (MS) is the most common disabling neurological condition [1-3].  
People with MS are less physically active than the general population [4] which leads 
to de-conditioning, a downward spiral of loss of functional capacity and reduced 
ability to perform activities and exercise.  It is widely agreed that exercise brings 
many benefits for people with MS including increased cardio-respiratory fitness, 
muscle strength and endurance, improved mood and enhanced ability to complete 
activities of daily living [5-7].  Other studies have shown improved cognition and 
executive functioning with periods of regular exercise in people with MS (pwMS) [8-
9] which were associated with improved mood and quality of life.  Secondary benefits 
of exercise include reduced risk of co-morbidities such as heart disease, increased 
cholesterol and osteoporosis [10-12].   
Exercise is therefore a fundamental component of the treatment strategy of pwMS.  
The mode of exercise people choose is driven by personal preference and capability 
[7].  However, exercise can be difficult for many pwMS due to e.g. symptoms, 
accessibility and transport.  The evidence base to support the benefits of exercise for 
pwMS with moderate to severe MS remains limited [13,14] and exercise options are 
especially limited [14,15]. 
Cycling is an exercise often adopted by people with neurological conditions as it is a 
safe, feasible option and improves aerobic endurance, muscle and bone strength, 
spasticity and function [15-20].  Cycling is similar to walking; they are both cyclical 
activities, involve reciprocal contraction and relaxation of major muscle groups of the 
lower limb and share sensori-motor control mechanisms [17,18,21].   
Lower limb active passive trainers (APT’s) are an alternative to ergometers. They 
can be used by people with all levels of disability as they provide cycling from a chair 
or wheelchair and the speed, resistance and type of exercise (active, active assisted 
or passive) can be adjusted depending on the user’s level of ability.  Users receive 
visual feedback on their speed, distance cycled actively and passively, power output 
and symmetry of cycling which increases motivation, facilitates motor 
learning/control and improves rehabilitation outcomes [16-18].   
Although APTs are used clinically, with anecdotal benefits, there is a paucity of 
evidence for their use in people with MS, especially those with higher levels of 
disability. The aim of this randomised controlled study was to evaluate the feasibility 
and potential effectiveness of a progressive, four week programme of exercise using 
lower limb APT (Motomed) in terms of lower limb spasticity, cardiovascular fitness, 
function and quality of life, in people with moderate to severe MS.  
 
Methods 
All those admitted to the Physical Disability Rehabilitation Unit at the Queen 
Elizabeth University Hospital, Glasgow, UK who fulfilled the inclusion and exclusion 
criteria were invited to take part.  To be included participants had to have a 
confirmed diagnosis of MS, be aged over 18 years and have an Expanded Disability 
Status Scale (EDSS) of between 6.0 and 8.5.  Participants were excluded if they had 
significant cognitive impairment such that they could not understand instructions, co-
morbidities which would preclude them taking part in exercise, visual impairment 
meaning they could not see the screen on the APT or were unable to be seated 
appropriately in a wheelchair for 30 minutes.  All participants gave written, informed 
consent and were randomly assigned to the intervention or control group, by 
choosing a sealed envelope which contained a piece of paper stating either control 
or intervention.   Ethical approval was granted by the West of Scotland Research 
Ethics Committee (reference 16/WS/0084) and research and development approval 
was obtained through NHS Greater Glasgow and Clyde (reference GN15PY148).  
Those in the APT group (intervention) were positioned on a chair or their wheelchair 
and received 30 minutes of APT cycling (2 minutes passive warm up, 26 minutes 
active cycling and 2 minutes passive cool down), five days per week for four weeks 
in addition to usual care (described below).  Each participant started the intervention 
at resistance level one, and the aim was to cycle at a speed that maintained a 
moderate intensity of exercise such that the exertion RPE score was between 12 
and 14 [22-24].  If the RPE, averaged over the exercise period, was 11 or below then 
the resistance level was increased at the next session, and if it was 15 or above then 
the resistance level was reduced.  Participants were encouraged to actively cycle 
however if they were unable to maintain this throughout the session the APT 
reverted to passive mode and continued.   
Those in the control group continued with usual care which was an individualised 
therapy programme, delivered Monday to Friday, and could include PT, OT, SLT and 
Psychology. 
For both groups at baseline, demographic details were recorded which included age, 
sex, type of MS, time since diagnosis, EDSS, past medical history, social 
circumstances, and mobility status.  Medication was recorded at the start and end of 
the study period and any changes in medications or relevant medical interventions 
throughout the study period were noted.   
Outcome measures were assessed the day before and after the four week study 
period by a research assistant who was blind to the group allocation.  The primary 
outcome measure was spasticity and was assessed using the MS spasticity scale 
(MSSS-88) and Modified Ashworth Scale (MAS).  The MSSS-88 is a self reported 
questionnaire which examines the effect of spasticity on aspects of daily life [25,26].  
The MAS is a six point ordinal scale (0-4) which grades the resistance during 
passive muscle stretching [25,27,28].  In this scale zero represents no increase in 
tone and four is graded where the affected part is rigid and unable to be moved.  
MAS scores were recorded for hip flexors, hip extensors, hip adductors, quadriceps, 
hamstrings, plantarflexors and invertors in both lower limbs of each participant.  
Secondary outcome measures were cardiovascular fitness measured using the  
Oxygen Uptake Efficiency Slope (OUES), Functional Independence Measure (FIM), 
Timed 25 Foot Walk Test (T25FW) and MS Quality of Life 54 (MSQOL-54).  
Cardiovascular fitness, measured using the OUES, has previously been validated as 
a sub-maximal test to gauge fitness in patients with MS [24-25].  Pulmonary gas 
exchange data was obtained during a fixed duration protocol using the Motomed 
APT; gas exchange data was collected at rest, during unloaded ‘passive’ cycling and 
then during ‘active’ cycling for eight minutes (all started at resistance level 0 and 
progressed every two minutes with progression based on the investigator’s clinical 
perception of the participants ability to maintain RPE between 12 and 14). 
Function was assessed by the FIM and T25FW.  The FIM consists of 18 items, 13 
motor tasks and five cognitive tasks required for daily living [31].  Each task is rated 
from one- requiring full assistance, to seven- independence in completing the task.  
Total scores range from 18 to 126 with higher scores indicating higher levels of 
independence.  The FIM has been shown to be valid, reliable and responsive in MS 
[32-34].  The T25FW was assessed in those who could walk.  In this test the time 
taken for the participant to walk along a 25 foot course as fast as they were able, 
using walking aids as required, was recorded [35].  Two metres were added at the 
start and end of the course for acceleration and deceleration.   
Quality of life was measured with the MSQOL-54, a condition specific, multi-
dimensional health-related quality of life measure [36].  The measure consists of 54 
questions and the two summary scores of physical and mental health were recorded.  
Participants who were unable to complete questionnaires on their own were assisted 
to complete them orally with the assessor.   
After each exercise session the following data were recorded from the APT: 
symmetry, distance cycled, power, average speed and resistance level. It has been 
reported that an increase of one grade of resistance is equivalent to an increase of 
1kg [16].   The inpatient therapy programme (usual care) each patient received 
within the study period was also recorded.   
 
Analysis 
Descriptive statistics were performed with estimates of effect size and an over view 
of the possible main effects observed from the outcome measures using repeated 
measures.  Demographics and outcome variables were summarised with group 
differences being tested using chi-square tests for categorical variables, two 
independent sample t-tests or Mann-Whitney tests where appropriate.  Simple linear 
regression was used to assess if any significant increases occurred from cycling 
outcomes variables (total distance, average rpm and power).  A 5% level of 
significance was used and all analysis was performed using IBM SPSSv24.  
 
Results 
Over the recruitment period 36 people with MS were admitted to PDRU, 33 met the 
inclusion criteria and were therefore invited to participate.  Eight patients declined to 
participate for various reasons which included being unable to commit to the study 
time period, concerns about managing the intensity of the intervention and the effect 
on fatigue (Figure 1).  Twenty five people were recruited to the study.  One 
participant dropped out due to a relapse therefore results are given for 24 
participants, 15 in the intervention and 9 in the control group. 
Figure 1 Near Here 
There was no significant difference between the groups at baseline for gender, age, 
EDSS or years since diagnosis (see Table 1).   
Table 1 Near Here 
There was 100% adherence rate to the cycling intervention (Table 2) with no 
adverse effects reported.  Simple linear regression was used to assess the 
relationship between the cycling variables and time and three were shown to be 
statistically significant, average speed cycled (R2 = 0.888, p= 0.026), power (R2 = 
0.866, p= 0.006) and the total distance cycled (R2 = 0.878, p= 0.032).  For each day 
cycling there was an average increase in distance of 0.04 miles, speed of 0.42 rpm 
and power of 0.32 watts.  There were no notably change in relation to leg symmetry 
however the median resistance level at start of the study was 1, by end was 2 (range 
of 0-7) (Table 2).   
Table 2 Near Here 
Participants received a therapy programme as standard care during the study and 
could include PT, OT, SLT and Psychology.  The average number of therapy 
sessions for each discipline was calculated for each participant in each group during 
the study period (see Table 3). 
Table 3 Near Here 
Following the intervention there were improvements in average scores for all 
outcome measures (see Table 4), but there were no significant difference between 
the intervention and control groups over time.   
Table 4 Near Here 
From the results of the MSSS-88 scores (Table 4) there was no significant group 
effect (p= 0.336).  On average both groups reported a reduction in perceived 
spasticity which was shown to be significant over time (p= 0.010).  The MSSS-88 
scores of the control group demonstrated a large size effect (0.76) while the 
intervention group showed a medium effect size (0.50) although there was no 
interaction effect (p= 0.699). 
     Table 5 & 6 Near here 
In terms of MAS spasticity levels were, on average, low and, in the intervention 
group, spasticity reduced from 1 to 0 in the right hip adductor muscles and increased 
from 0 to 1 in right and left soleus muscle.  In the control group spasticity reduced in 
the right and left hip adductor muscles and left gastrocnemius muscle changing from 
1 to 0 in both groups.  There were no changes in any of the other muscle groups for 
either intervention or control groups.    
Of the 24 participants only 11 were able to complete the T25FW at baseline, 8 from 
the intervention group and 3 from the control group (Table 4).  However an additional 
4 participants were able to complete the test post-intervention, 3 from the 
intervention group and 1 from the control group.  The results in Table 4 however are 
from the 11 subjects who completed both pre and post-intervention 25FTW.  From 
these 11 participants there was no significant group effect (p= 0.302).  Furthermore, 
no overall time or interaction effects were detected (p= 0.586 and 0.345 
respectively).  Calculating effect sizes for the T25FW was inappropriate given so few 
participants completed the test at both time points and the unequal number of 
participants in the groups (control n= 3 and intervention n= 8).   
There was no significant group effect for the FIM scores (p= 0.290).  However there 
was a significant increase in total score over time (p < 0.001) with the control group 
demonstrating a large effect size (0.73) and the intervention group a medium effect 
size (0.31). There was no interaction effect (p= 0.149). 
Improvements were shown across both physical health (PH) and mental health (MH) 
domains in the MSQOL-54.  There was no significant group effect for either PH (p= 
0.631) or MH (p= 0.838) domains.  Overall, there was a significant time effect for 
both domains, PH (p= 0.007) and MH (p= 0.029).  In addition a large effect size was 
demonstrated for the intervention group (0.93) and medium effect size in the control 
group (0.46).  Again there was no interaction effect for PH (p= 0.385) or MH (p= 
0.986).   
There was no significant group effect for the OUES scores (p = 0.838) (Table 4).  
Overall there was no significant time effect (p = 0.535) nor interaction effect (p = 
0.325).  The control effect size was negligible (0.07) whilst the intervention group 
yielded medium effect size (0.36).  
 
Discussion 
The study demonstrated that an APT exercise programme is feasible option for 
people with moderate to severe MS who are in-patients in a rehabilitation ward.  In 
addition the results suggested that most people (33/36) fulfilled the inclusion criteria 
and of those around 75% (25/33) agreed to take part. These figures help to 
determine the recruitment strategy of any subsequent study in this area. 
Improvements were noted in the majority of outcome measures, although no 
statistically significant group differences were found.  The average power output, 
distance cycled and speed improved in the intervention group this did not translate to 
statistical changes in the outcome measures.  There was also 100% adherence to 
the cycling intervention, with no adverse effects reported, showing it to be a safe and 
acceptable treatment option.  
Spasticity 
There were minimal changes in spasticity for both groups, although participants in 
both groups perceived spasticity changed from the MSSS-88 results, which was 
shown to be significant over time (p= 0.010).  The median MAS scores were also 
found to be much lower in both groups than anticipated and were considered 
minimal with no patterns found.  This may have resulted in a floor effect of the MAS.  
Overall there was no difference between groups, although the study was not 
powered detect a difference.   
From the previous studies that have considered the effect of cycling on lower limb 
spasticity in pwMS [15,19,20,37,38], only two have used APTs [15,19] and only one 
considered the effects of a cycling programme [38], the other examined a single 
session of exercise [15].  A further study with a group of participants with various 
neurological conditions, also included pwMS [19].  In the study by Sosnoff et al 
(2009) participants cycled on an ergometer for 30 minutes, three times a week for a 
month.  Like the current study, Sosnoff et al (2009) found no objective change in 
spasticity after the cycling intervention when measured by either neurophysiology or 
MAS scores.  In comparison Szecsi et al (2009) showed significant reduction in MAS 
scores (p= 0.05) after six APT sessions.  Rosche et al (1997) showed reduction in 
mean F wave/M response ratio (p< 0.001) immediately after a single session of 30 
minutes of cycling using an APT, however as mentioned previously, this study 
included participants with other neurological conditions in addition to pwMS.  Other 
studies have also demonstrated spasticity to be significantly reduced for up to one 
hour after a single session of ergometer cycling, as opposed to APT cycling in pwMS 
[20,37].   
The lack of objective change in spasticity within this study could be due to the 
outcome measures used and the study design.  While the MAS is the most 
universally used measure of spasticity it only quantifies passive resistance or limb 
stiffness, it does not measure the neural components that contribute to spasticity [39-
41].  Other studies have found neurophysiology tests to be more sensitive in the 
detection of spasticity compared to the MAS [38,41-44].   
Function 
During this study only 11 participants completed the pre and post T25FW test, eight 
from the intervention group and three from the control.  However at the end of the 
study a further three participants in the intervention group and one from the control 
group were able to complete the T25FW.     
The minimal clinically important difference (MCID) for the T25FW in pwMS is 
reported to be 17.2% [46].  Seven participants in the intervention group and two in 
the control group improved their walking speed by more than the MCID, thus 
representing an important change in function for these participants.      
Although the T25FW test is one of the most used clinically, no other study has used 
it as an outcome measure when considering the effects of cycling in pwMS.  Several 
studies have used alternative walking measures such as the 6MWT, 10MWT or 
other timed motor tests.  The majority of these studies showed significant 
improvement in walking performance after a cycling intervention [16,47-49].  While 
the results of this study did not show statistically significant improvements this was 
likely down to the small numbers of participants who were able to complete both pre 
and post assessments. 
Health Related Quality Of Life (HRQOL) 
In relation to quality of life, the results of this study showed improvements across 
both physical health (PH) and mental health (MH) domains in the MSQOL-54.  
However, the MCID has not been established [50].   
Few studies have used quality of life measures when considering the effects of a 
programme of cycling on pwMS [51-53].  Rampello et al (2007) used the MSQOL-54 
to investigate the effects of an eight week cycling programme and showed significant 
improvements in three subgroups of the MSQOL-54 (emotional well being, energy 
and health distress).  Other studies have used the SF-36 [51-53], the measure from 
which the MSQOL-54 was developed.  While Cakit et al (2010) found significant 
improvements in physical functioning and role-physical functioning, from the SF-36, 
over an eight week intervention, Mostert et al (2010) found significant improvements 
in social functioning and vitality after a four week intervention.  All of these studies 
however used ergometers to cycle, and no studies of APTs in pwMS included 
HRQOL measures.  
Cardiovascular fitness 
This study showed a small improvement in OUES scores in the intervention group 
however there were no significant differences between groups demonstrated.  
Fitness is improved due to peripheral and central adaptations, thus the training must 
be at a sufficient dose in terms of intensity, duration and frequency.  Endurance 
training leads to peripheral adaptations first, with increases in the concentration of 
oxidative enzymes and mitochondria within the muscle fibres [54,55], and an 
increase in number of capillaries around these fibres.  These permit increased 
muscle blood flow and venous return an in combination these changes make the 
muscle more efficient and resistant to fatigue [55,56].  Central adaptations take 
longer to occur studies; suggesting 6-12 months of cycling intervention at 60-70% 
VO2peak or 60-80% of HRmax is required [13,57].  However, another study 
demonstrated cardiac and skeletal muscles changes as early as 3 weeks which 
continued during a 12 week trial [58].  Their training programme consisted of 3 x 
week cycling sessions for 45 minutes at power output that elicited 70% of VO2max.  In 
the current study the improvements in the average total distance cycled, speed and 
power output would suggest peripheral adaptations may have occurred due to 
cycling.  However given the disability levels of the participants, a longer study would 
perhaps be needed to elicit the central changes required to show a change in 
cardiovascular fitness.   
 
Limitations 
There were several limitations to this study.  The study included only in-patients who 
were receiving an intensive period of therapy as ‘usual care’, making it difficult to 
separate the effects of the in-patient therapy programme from any effects of the 
cycling intervention.  Whilst previous studies have exercised participants up to 90% 
of maximal heart rate (REF) we did not feel this was appropriate for our participant 
already undergoing an intense rehabilitation programme.  In addition, participants in 
both groups underwent medication changes or procedures that could have 
influenced clinical measures. The outcome measures were assessed the day before 
and the day after completion of the study period, and for several participants their 
last exercise session was a Friday and the assessment was on Monday.  This may 
have resulted in the treatment effects from cycling may have been lost, as studies 
have shown the antispasticity effects of cycling to be present immediately after the 
exercise period [15,20,37].  Lastly with 24 participants this study had a small sample 
and was not powered to show statistically significant changes.  Based on the data 
generated from the MSSS-88, it was estimated that groups of 38 participants would 
be required to detect significant group differences with an 80% power.   
 
Conclusion 
This study has demonstrated that daily cycling for 30 minutes is a feasible and safe 
exercise option for people moderately to severely affected by MS.  It produced no 
adverse effects or increase in symptoms in any participants, and participants were 
able to tolerate the intensity of treatment as demonstrated by 100% adherence to the 
intervention programme.  Although the majority of outcome measures improved, this 
was not statistically significant, however pwMS were able to cycle for longer and with 
a higher power output.  A fully powered, study of APT cycling over a longer of period 
of time and using community dwelling people, who would not be receiving concurrent 
intensive therapy, is merited to further determine the effects of APT cycling in people 
moderately to severely affected by MS.  
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Patients admitted with 
diagnosis of MS (n= 36) 
Did not meet inclusion criteria  
(n= 3) 
 
Completed the study (n= 15) 
 Excluded from analysis (n= 1) 
Allocated to intervention (n= 16) 
 Received allocated intervention  
(n= 15) 
 Did not receive allocated intervention 
(n= 1) 
Allocated to control (n= 9) 
 Received allocated intervention  
(n= 9) 
 
Completed the study (n= 9) 
 Excluded from analysis (n= 0) 
 
Randomised (n= 25) 
Declined (n= 3) 
Unable to commit to 20 sessions  
(n= 5) 
Worried about fatigue/intensity (n= 
3) 
 
Invited to participate (n= 33) 
  
Table 1 Summary of participant demographic variables 
 Intervention Group 
(n = 15) 
Control Group 
(n = 9) 
Significance of 
Group Factor 
Gender (M/F) 6/9 (40%/60%) 3/6 (33%/67%) 1.000c 
Age (yrs)  
(mean ± SE) 
54.9 ± 2.6 53.6 ± 2.7 0.739a 














Years since diagnosis 
(mean ± SE) 
14.6 ± 2.3 16.9 ± 4.5 0.609a 
EDSS score  
(mean ± SE) 
7.2 ± 0.2 7.3 ± 0.2 0.665a 














Education status: n(%) 
University 
College 






















a two-sample t-test; b chi-square test; c Fisher’s Exact test; PPMS (primary progressive MS);  
SPMS (secondary progressive MS); RRMS (relapsing and remitting MS); EDSS (Extended 
disability status scale). 
Table 2 Cycling variables - Day 1 and Day 20 
 1st session  
(Day 1) 
20th session  
(Day 20) 
p-value* 
Duration active (min)  25.9 ± 0.0 25.8 ± 0.2 0.446a 
Duration passive (min) 4.0 ± 0.0 4.1 ± 0.2 0.446a 
Distance active (miles)  3.4 ± 0.3 3.9 ± 0.5 0.145b 
Total distance (miles) 3.5 ± 0.3 4.2 ± 0.4 0.032b 
Revolutions per minute 
(rpm) 
42.2 ± 3.5 50.5 ± 4.3 0.026b 
Power (W) (n=13) 7.2 ± 1.1 13.6 ± 2.8 0.006a 
All values mean ± SE; * data analysed with a wilcoxon test;  b paired t-test 
Table 3 Summary of usual care  
Therapy Average no of 
therapy sessions  -
Intervention group 
Average no of therapy 
sessions – Control group 
PT  29 ± 3 29 ± 6 
OT 9 ± 6 15 ± 8 
SLT  1 ± 1 1 ± 1 
Psychology 1 ± 2 1 ± 1 
 















MSSS 88 238 ± 17 204 ± 16 220 ± 22 176 ± 21 p= 0.336 




39 ± 22 
(n=3) 
23 ± 29 
(n=3) 
p= 0.302 





28 ± 4 
52 ± 7 
 
43 ± 4 
63 ± 7 
 
34 ± 5 
54 ± 9 
 
42 ± 6 















All values mean ± SE 
Table 5 Intervention group median MAS scores 
Intervention group Right Leg Left Leg 
 Pre Post Pre Post 
Hip flexors 0 0 0 0 
Hip extensors 0 0 0 0 
Adductors 1 0 0 0 
Quadriceps 1 1 0 0 
Hamstrings 0 0 0 0 
Gastrocnemius 1 1 1 1 
Soleus 0 1 0 1 
Invertors 0 0 0 0 
 
Table 6 Control group median MAS score 
Control group Right Leg Left Leg 
 Pre Post Pre Post 
Hip flexors 0 0 0 0 
Hip extensors 0 0 0 0 
Adductors 1 0 1 0 
Quadriceps 0 0 0 0 
Hamstrings 0 0 0 0 
Gastrocnemius 1 1 1 0 
Soleus 1 1 1 1 
Invertors 0 0 0 0 
 
 
 
